Gross-to-Net Product Sales and Significant Customers (Tables)

12 Months Ended

Dec. 31, 2016

Revenue, Net [Abstract]

Reconciliation of Gross to Net Product Sales

The below table presents a GTN product sales reconciliation for the accompanying Consolidated Statement of Operations:

	2016			2015			2014
Gross product sales	$	244,770		$	215,136		$	284,685
Commercial rebates and government chargebacks	(98,317		)	(61,283		)	(76,636		)
Data and distribution fees, GPO fees, and inventory management fees	(14,979		)	(15,613		)	(21,330		)
Prompt pay discounts	(755		)	(16		)	(260		)
Product returns allowances	(2,123		)	(1,373		)	78
Net product sales	$	128,596		$	136,851		$	186,537

Schedule of Revenue by Major Customers by Reporting Segments

The below table presents the customers that represent 10% or more of our gross product sales in 2016, 2015, and 2014:

	Year Ended December 31,
	2016				2015				2014
AmerisourceBergen Corporation, and its affiliates	$	93,951	38.4	%	$	78,989	36.7	%	$	115,079	40.4	%
McKesson Corporation and its affiliates	75,952		31.0	%	73,577		34.2	%	93,656		32.9	%
Cardinal Health, Inc. and its affiliates	58,780		24.0	%	37,414		17.4	%	*		—	%
All other customers	16,087		6.6	%	25,156		11.7	%	75,950		26.7	%
Gross product sales	$	244,770	100.0	%	$	215,136	100.0	%	$	284,685	100.0	%

* Less than 10%

The below table presents our license fees and service revenue by source for the years ended December 31, 2016, 2015, and 2014:

	Year Ended December 31,
	2016				2015				2014
Out-license of ZEVALIN, FOLOTYN, BELEODAQ, MARQIBO: upfront receipt for the Canada territory (Note 17(b)(xiv))	$	6,000	33.6	%	$	—	—	%	$	—	—	%
Sales and marketing contracted services (Note 14)	9,096		51.0	%	—		—	%	—		—	%
Out-license of ZEVALIN: upfront receipts and royalties for Asia and certain other territories, excluding China (Note 12)	1,756		9.8	%	15,144		58.9	%	—		—	%
Out-license of FOLOTYN in all countries except the U.S., Canada, Europe, and Turkey (Note 16)	927		5.2	%	831		3.2	%	293		100.0	%
Out-license of ZEVALIN, MARQIBO, EVOMELA: upfront receipt for the China territory (Note 11)	—		—	%	9,682		37.7	%	—		—	%
Out-license of ZEVALIN: amortization of upfront receipt related to India territory (Note17(b)(iii)) and other	69		0.4	%	48		0.2	%	—		—	%
License fees and service revenues	$	17,848	100.0	%	$	25,705	100.0	%	$	293	100.0	%